These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


138 related items for PubMed ID: 9259409

  • 1. CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro exhibits anti-tumor activity.
    Camoratto AM, Jani JP, Angeles TS, Maroney AC, Sanders CY, Murakata C, Neff NT, Vaught JL, Isaacs JT, Dionne CA.
    Int J Cancer; 1997 Aug 07; 72(4):673-9. PubMed ID: 9259409
    [Abstract] [Full Text] [Related]

  • 2. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
    George DJ, Dionne CA, Jani J, Angeles T, Murakata C, Lamb J, Isaacs JT.
    Cancer Res; 1999 May 15; 59(10):2395-401. PubMed ID: 10344749
    [Abstract] [Full Text] [Related]

  • 3. Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587).
    Dionne CA, Camoratto AM, Jani JP, Emerson E, Neff N, Vaught JL, Murakata C, Djakiew D, Lamb J, Bova S, George D, Isaacs JT.
    Clin Cancer Res; 1998 Aug 15; 4(8):1887-98. PubMed ID: 9717816
    [Abstract] [Full Text] [Related]

  • 4. Gö 6976 is a potent inhibitor of neurotrophin-receptor intrinsic tyrosine kinase.
    Behrens MM, Strasser U, Choi DW.
    J Neurochem; 1999 Mar 15; 72(3):919-24. PubMed ID: 10037462
    [Abstract] [Full Text] [Related]

  • 5. K-252b potentiation of neurotrophin-3 is trkA specific in cells lacking p75NTR.
    Maroney AC, Sanders C, Neff NT, Dionne CA.
    J Neurochem; 1997 Jan 15; 68(1):88-94. PubMed ID: 8978713
    [Abstract] [Full Text] [Related]

  • 6. Oncogenic activation of the tyrosine kinase domain of the human trk proto-oncogene by fusion to a cell adhesion molecule.
    Albor A, Thraves PJ, Dritschilo A, Notario V.
    Oncogene; 1996 Oct 17; 13(8):1755-63. PubMed ID: 8895522
    [Abstract] [Full Text] [Related]

  • 7. Kinetics of trkA tyrosine kinase activity and inhibition by K-252a.
    Angeles TS, Yang SX, Steffler C, Dionne CA.
    Arch Biochem Biophys; 1998 Jan 15; 349(2):267-74. PubMed ID: 9448714
    [Abstract] [Full Text] [Related]

  • 8. Suppression of p140trkA does not abolish nerve growth factor-mediated rescue of serum-free PC12 cells.
    Taglialatela G, Hibbert CJ, Hutton LA, Werrbach-Perez K, Perez-Polo JR.
    J Neurochem; 1996 May 15; 66(5):1826-35. PubMed ID: 8780007
    [Abstract] [Full Text] [Related]

  • 9. Transphosphorylation of the neurotrophin Trk receptors.
    Canossa M, Rovelli G, ShooterEM.
    J Biol Chem; 1996 Mar 08; 271(10):5812-8. PubMed ID: 8621450
    [Abstract] [Full Text] [Related]

  • 10. P53 associates with trk tyrosine kinase.
    Montano X.
    Oncogene; 1997 Jul 17; 15(3):245-56. PubMed ID: 9233759
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of phosphorylation of TrkB and TrkC and their signal transduction by alpha2-macroglobulin.
    Hu YQ, Koo PH.
    J Neurochem; 1998 Jul 17; 71(1):213-20. PubMed ID: 9648868
    [Abstract] [Full Text] [Related]

  • 12. K252a is a selective inhibitor of the tyrosine protein kinase activity of the trk family of oncogenes and neurotrophin receptors.
    Tapley P, Lamballe F, Barbacid M.
    Oncogene; 1992 Feb 17; 7(2):371-81. PubMed ID: 1312698
    [Abstract] [Full Text] [Related]

  • 13. The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness.
    Miknyoczki SJ, Dionne CA, Klein-Szanto AJ, Ruggeri BA.
    Ann N Y Acad Sci; 1999 Jun 30; 880():252-62. PubMed ID: 10415871
    [Abstract] [Full Text] [Related]

  • 14. Expression of TRK-T1 oncogene induces differentiation of PC12 cells.
    Greco A, Orlandi R, Mariani C, Miranda C, Borrello MG, Cattaneo A, Pagliardini S, Pierotti MA.
    Cell Growth Differ; 1993 Jul 30; 4(7):539-46. PubMed ID: 8398895
    [Abstract] [Full Text] [Related]

  • 15. The selective and inducible activation of endogenous PI 3-kinase in PC12 cells results in efficient NGF-mediated survival but defective neurite outgrowth.
    Ashcroft M, Stephens RM, Hallberg B, Downward J, Kaplan DR.
    Oncogene; 1999 Aug 12; 18(32):4586-97. PubMed ID: 10467403
    [Abstract] [Full Text] [Related]

  • 16. Analysis of the trk NGF receptor tyrosine kinase using recombinant fusion proteins.
    Horvath CM, Wolven A, Machadeo D, Huber J, Boter L, Benedetti M, Hempstead B, Chao MV.
    J Cell Sci Suppl; 1993 Aug 12; 17():223-8. PubMed ID: 8144701
    [Abstract] [Full Text] [Related]

  • 17. Extended ceramide exposure activates the trkA receptor by increasing receptor homodimer formation.
    MacPhee I, Barker PA.
    J Neurochem; 1999 Apr 12; 72(4):1423-30. PubMed ID: 10098845
    [Abstract] [Full Text] [Related]

  • 18. TrkA mediates the nerve growth factor-induced intracellular calcium accumulation.
    De Bernardi MA, Rabins SJ, Colangelo AM, Brooker G, Mocchetti I.
    J Biol Chem; 1996 Mar 15; 271(11):6092-8. PubMed ID: 8626395
    [Abstract] [Full Text] [Related]

  • 19. Nerve growth factor induced stimulation of Ras requires Trk interaction with Shc but does not involve phosphoinositide 3-OH kinase.
    Hallberg B, Ashcroft M, Loeb DM, Kaplan DR, Downward J.
    Oncogene; 1998 Aug 13; 17(6):691-7. PubMed ID: 9715270
    [Abstract] [Full Text] [Related]

  • 20. Phosphotyrosine residues in the nerve-growth-factor receptor (Trk-A). Their role in the activation of inositolphospholipid metabolism and protein kinase cascades in phaeochromocytoma (PC12) cells.
    Baxter RM, Cohen P, Obermeier A, Ullrich A, Downes CP, Doza YN.
    Eur J Biochem; 1995 Nov 15; 234(1):84-91. PubMed ID: 8529673
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 7.